Who is sponsoring NCT01739023?

NCT01739023 is sponsored by W. Dalton Dietrich.

What condition does NCT01739023 study?

NCT01739023 studies Spinal Cord Injury, Paraplegia.

What drugs are being tested in NCT01739023?

Interventions: Autologous Human Schwann Cells.

What is the status of NCT01739023?

NCT01739023 is currently COMPLETED.

Last reviewed 2019-03-04 · How we verify

The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute Spinal Cord Injury (SCI)

NCT01739023 Phase 1 COMPLETED

The purpose of this study is to assess the safety of autologous human Schwann cells (ahSC) transplantation in subjects with subacute SCI. For humans with subacute SCI, we hypothesize that axons might show improved function if myelin repair is induced with the implantation of ahSC. In addition spinal cord cavitation may be reduced, and neural sprouting and plasticity may be enhanced via neurotrophic effects.

Details

Lead sponsor	W. Dalton Dietrich
Phase	Phase 1
Status	COMPLETED
Enrolment	9
Start date	2012-11
Completion	2016-08

Conditions

Spinal Cord Injury
Paraplegia

Interventions

Autologous Human Schwann Cells

Primary outcomes

International Standards of Neurological Classification for Spinal Cord Injury — Change from Baseline at 12 months
MRI of spinal cord — Change from Baseline at 12 months
Neuropathic pain — Change from Baseline at 12 months

Countries

United States